us to hypothesize that similar benefits could be achieved during exercise with inhaled β-agonists. To test this hypothesis, we conducted this randomized controlled trial to determine whether the inhaled β-agonist albuterol would improve pulmonary vascular function during exercise in patients with HFpEF.
Methods
The data, analytical methods, and study materials will not be made available to other researchers.
This double-blind, randomized, placebo-controlled, parallelgroup trial was designed to study the effects of inhaled, nebulized albuterol on pulmonary vascular hemodynamics and cardiac function at rest and during exercise in subjects with HFpEF. Patients referred to the Mayo Clinic cardiac catheterization laboratory for invasive hemodynamic exercise testing in the evaluation of unexplained dyspnea were enrolled. Written informed consent was obtained from all patients. The study was approved by the Mayo Clinic Institutional Review Board, and the trial was registered (NCT02885636; BEAT HFpEF [Inhaled Beta-Adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction]).
Study Population
Subjects were consented before catheterization and qualified for randomization if they demonstrated hemodynamic evidence of HFpEF by resting end-expiratory pulmonary capillary wedge pressure (PCWP; ≥15 mm Hg) or an exercise PCWP (≥25 mm Hg) at a 20 W workload. 23, 24 Patients with significant left-sided valvular heart disease (>mild stenosis, >moderate regurgitation), coronary disease requiring revascularization, infiltrative, restrictive or hypertrophic cardiomyopathies, constrictive pericarditis, significant obstructive or restrictive pulmonary disease, high-output heart failure (HF), albuterol use within 48 hours, prior ejection fraction <50%, pulmonary embolism, and RV myopathies were excluded.
Overall Design
All studies were performed in the supine position on chronic medications in the fasted state using the invasive hemodynamic exercise testing protocol as described previously. 25, 26 After assessment of baseline (resting) hemodynamics, subjects underwent supine cycle ergometry exercise with simultaneous expired gas analysis at a fixed workload of 20 W (pedal speed, 60 rpm) for 5 minutes, with repeat assessment of hemodynamics. After exercise, a period of ≥5 minutes was allowed for recovery to reestablish baseline vital signs. Subjects then received study drug in a randomized, double-blind fashion, with repeat assessment of resting and exercise hemodynamics in the exact same manner as above. 25, 26 Randomization was performed using a random number generator in SAS (SAS Institute, Inc, Cary, NC) in permuted blocks of 10.
Hemodynamic Assessment
Right heart catheterization was performed through a 9F sheath via the right internal jugular vein as described previously. 9, 18, 25, 26 Mean right atrial (RA) pressure, PA pressures, and PCWP were measured using a high-fidelity micromanometer (Aeris; St. Jude Medical) advanced through the lumen of a 7F fluid-filled catheter (balloon wedge, arrow). PCWP position was confirmed by appearance on fluoroscopy, characteristic pressure waveforms, and oximetry (saturation, ≥94%). All pressures were taken as the average across multiple respiratory cycles during a 15-second period, reflecting the mean of 750 to 2000 cardiac cycles. Pressure tracings were recorded, digitized (240 Hz), and stored for offline analysis by one investigator experienced in exercise hemodynamic assessment (B.A.B.).
Breath-by-breath oxygen consumption (VO 2 ) was measured continuously throughout each phase of the study (MedGraphics, St. Paul, MN). A 4F to 6F radial arterial cannula was used to measure arterial blood pressure and allow sampling of arterial blood gases. Simultaneous PA blood samples were obtained to measure systemic and mixed venous O 2 contents (=saturation×hemoglobin×1.34). Arterial-venous O 2 content difference (AVO 2 diff) was calculated from systemic arterial and PA O 2 contents. Cardiac output (Q C ) was calculated by the direct Fick method (=VO 2 /AVO 2 diff). Stroke volume (SV) was calculated as the quotient of Q C and heart rate (HR). Pulmonary vascular resistance (PVR) was calculated as (mean PA−PCWP)/Q C , PA compliance by the ratio of SV/PA pulse pressure, and PA elastance by the ratio of PA systolic pressure/SV. 9, 25, 26 Systemic vascular resistance was calculated by (mean blood pressure−RA pressure)/Q C .
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Novelty and Significance
What Is Known?
• Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction, but no therapies are available that target this abnormality.
• Enhancing pulmonary vasodilation at rest and during exercise might be beneficial in heart failure with preserved ejection fraction but could also worsen left atrial hypertension, exacerbating lung congestion.
What New Information Does This Article Contribute?
• Albuterol-an inhaled β-adrenergic agonist-enhanced pulmonary vasodilation during exercise compared with placebo, reducing pulmonary artery pressures.
• This was coupled with enhanced cardiac output reserve and reduced right heart congestion during exercise, without an increase in leftsided filling pressures.
In this double-blind placebo-controlled trial, we demonstrate that albuterol improves pulmonary vasodilation during exercise, effects that were coupled with enhanced forward cardiac output, reduced right atrial pressure, improved left heart distention, and enhanced right ventricular pulmonary artery coupling in patients with heart failure with preserved ejection fraction. This pulmonary vasodilation and increase in flow occurred without an untoward increase in left-sided filling pressures. These data support future trials aimed at improving pulmonary vasodilation during stress with β-agonists or other therapies. January 18, 2019
Although PCWP reflects the hydrostatic pressure distending the lung capillaries, it does not adequately reflect the net distending pressure that determines LV preload, which is quantified by LV transmural pressure. 18, [27] [28] [29] The total pressure measured in the LV during diastole (estimated by PCWP) is equal to the sum of transmural pressure and the external pressure applied to the LV from the pericardium and right heart. As shown by Tyberg et al, 27 this external pressure is best estimated by RA pressure; so LV transmural pressure is calculated as PCWP minus RA pressure. 18, 28, 29 Assessment of RV Function and RV-PA Coupling Echocardiography was performed simultaneously at rest and during exercise as previously described to assess RV function. 9, 24, 30 Tricuspid annular plane systolic excursion, RV systolic tissue velocity at the lateral tricuspid annulus (RV s′), and fractional area change were measured at each stage. RV dysfunction was defined according to the American Society of Echocardiography recommendations as either RV fractional area change <35% or RV s′ <10 cm/s (or both). 30 RV-PA coupling was assessed by the ratio of tricuspid annular plane systolic excursion to PA pressure as in prior studies. 31, 32 Ratios of fractional area change and RV s′ to PA pressure were also examined as complementary indices of RV-PA coupling analogous to tricuspid annular plane systolic excursion/PA pressure ratio.
Study Drug Intervention
After the first exercise phase was completed and hemodynamics returned to baseline, subjects were randomized 1:1 to either inhaled placebo (normal saline solution) or inhaled albuterol sulfate (2.5 mg) administered through a high-efficiency nebulizer (Solo-Idehaler Device; Aerogen Galway, Ireland/DTF Saint-Etienne, France). 25 The albuterol/placebo solutions were identical in appearance and prepared by research pharmacy, ensuring blinding of both participants and investigators.
Study End Points and Sample Size Considerations
The primary end point of the trial was PVR during exercise. Exercise PVR was chosen rather than rest PVR because hemodynamic perturbations are known to be greater during exercise in HFpEF (where patients are symptomatic) as compared with rest 6 and based on our prior observation of abnormal PVR during exercise but not rest in HFpEF. 9 Secondary end points included resting PVR, as well as rest and exercise PCWP, PA compliance, RA pressure, PA pressure, Q C , SV, RV systolic function, and RV-PA coupling .
The sample size of 30 patients (15 in each arm) was determined based on power calculations from our prior data testing the effects of dobutamine, where PVR was reduced by 0.8 WU in subjects with HFpEF. 22 Assuming an SD of 0.5 WU in exercise PVR based on our prior data, 25, 26 this sample size was estimated to provide 98% power (α=0.05) to detect a reduction in exercise PVR of this magnitude or greater with albuterol as compared with placebo.
Statistical Analysis
Data are presented as mean (SD), median (interquartile range), or number (%). Between-group differences were compared by unpaired t test, Wilcoxon rank-sum test, χ 2 , or Fisher exact test as appropriate. Changes between rest and exercise hemodynamics before study drug were compared by paired t test. ANCOVA was used to determine the effect of albuterol on exercise PVR using the initial exercise PVR (before study drug) as the covariate. 25, 26 Linear regression analyses were used to assess relationships between changes in variables of interest. Analysis was performed using JMP 13.0.0 (SAS). A P value of <0.05 was considered statistically significant.
Results
Study Population
Of 40 subjects enrolled, 10 did not meet eligibility criteria and were therefore not randomized (6 had normal rest and exercise hemodynamics, 1 left-to-right shunt, 1 highoutput HF, 1 found to have coronary disease necessitating revascularization, and 1 group 1 pulmonary hypertension [PH] ). The remaining 30 subjects qualified and were randomized. Subjects were older aged, obese, and hypertensive, representing a typical HFpEF population. There were no differences in baseline characteristics in subjects randomized to placebo or albuterol (Table 1) .
Baseline Hemodynamics and Right Heart Structure Before Randomization
As expected, mean PA pressure and biventricular filling pressures were elevated at rest and became markedly elevated with exercise, with mildly elevated PVR at rest that failed to decline during exercise ( Table 2 ). There was a slightly lower exercise PCWP in the HFpEF subjects randomized to albuterol but no other group differences in rest or exercise hemodynamics ( Table 2 ). Values represent mean±SD or median [interquartile range]. There were no significant differences between the placebo and albuterol groups in baseline characteristics. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; E/e′, ratio of early diastolic transmitral filling velocity (E) and early diastolic mitral annular tissue velocity (e′); LA, left atrial; LV, left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RV, right ventricular; and s′, systolic tissue Doppler velocity at the lateral tricuspid annulus.
*RV dysfunction was defined by American Society of Echocardiography recommendations as either RV FAC <35% or RV s′ <10 cm/s.
After the initial exercise period, all hemodynamics returned to baseline values, with the exception of heart rate, which was slightly elevated at rebaseline assessment as compared with the initial baseline (74±13 versus 71±11 bpm; P<0.001; Online Table I ). However, importantly, there were no differences in rebaseline heart rate or other hemodynamics between subjects randomized to albuterol and placebo (Online Table II ).
Effect of Albuterol on Resting Hemodynamics
Albuterol decreased RA pressure and systemic blood pressure at rest with a trend toward higher LV transmural pressure (P=0.07) but had no effect on heart rate, SV, systemic vascular resistance, or Q C (Table 3; Online Table III) . Mean PA pressure (P=0.08) and PA elastance (P=0.09) tended to decrease at rest with albuterol, with no significant change in resting PVR or PA compliance. RV-PA coupling improved at rest, as reflected by increases in the ratios of RV s′ and fractional area change to mean PA pressure, although the tricuspid annular plane systolic excursion/PA pressure ratio did not change at rest after albuterol treatment (Table 3) .
Effect of Albuterol on Exercise Hemodynamics
The primary end point of exercise PVR was significantly improved with albuterol, with a 35% reduction in exercise PVR (−0.6±0.5 versus +0.1±0.7 WU; P=0.003 by t test; P=0.003 by ANCOVA; Table 4; Figure 1 ). As compared with placebo, albuterol improved PA compliance and arterial elastance, enhanced RV-PA coupling, improved cardiac output and SV reserve, and lowered RA pressure with exercise (Table 4 ; Figure 1 ; Online Table III) . Mean PA pressure decreased, despite an increase in blood flow through the lungs, with a significant reduction in the slope of the PA pressure-flow relationship (change in ∆PA/∆Q C : −1.4±0.8 versus −0.2±0.6 mmHg/L•min -1 ; P=0.0002 by t test; P=0.005 by ANCOVA; Figure 2 ).
Albuterol improved cardiac output reserve with exercise by 25% (Figure 2) , with an increase in Q C reserve relative to whole-body O 2 consumption (ΔQ C /ΔVO 2 slope: +1.6±2.8 versus −0.3±2.1 ml/ml; P=0.04). The improvement in exercise cardiac output with albuterol was predominantly related to an increase in SV (R 2 =0.8; P<0.0001) rather than change in heart rate (R 2 =0.2; P=0.09). Albuterol also reduced exercise blood pressure and systemic vascular resistance and enhanced RV-PA coupling during exercise (Table 4) .
Despite a substantial increase in blood flow through the lungs, albuterol did not increase PCWP at rest or during exercise compared with placebo (Tables 3 and 4 ). However, there was an improvement in LV transmural pressure, which is more strongly related to LV chamber volume at end diastole (Table 4) . [27] [28] [29] Notably, the magnitude of decrease in exercise PVR was correlated with greater increase in LV transmural pressure during exercise (Figure 3 ). This suggests that pulmonary vasodilation improved the ability to augment LV filling and thus better utilize the Frank-Starling mechanism, even as pulmonary venous pressure during exercise remained unchanged. 
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Discussion
In this randomized, double-blind, placebo-controlled trial, we evaluated the effect of the inhaled β-adrenergic agonist albuterol-an inexpensive and widely available drug-on pulmonary vascular function and cardiac hemodynamics at rest and during exercise in patients with HFpEF. We demonstrate that albuterol exerts favorable effects on pulmonary vascular load during exercise, even among patients without marked elevation in PVR, which is coupled with significant improvements in cardiac output reserve, RV-PA coupling, and left heart filling (transmural pressure), without increasing pulmonary capillary hydrostatic pressures. Further study is needed to evaluate the chronic efficacy of β-agonists in HFpEF, as well as other forms of pulmonary hypertension.
Pulmonary Vascular Disease as a Therapeutic Target in HFpEF
Pulmonary hypertension is common and associated with adverse outcomes in HFpEF. [1] [2] [3] [4] [5] [6] [7] [8] RV dysfunction develops in HFpEF in response to chronic PH, and its presence identifies patients at high risk of death. 4, 15, 16 Although trials in PH have generally moved toward requiring higher PVR for inclusion, recent data have revealed that even in the earliest stages of HFpEF, where PVR is normal at rest, there are impairments in PA vasodilation and RV functional reserve that become manifest during exercise, which are directly correlated with impairment in peak aerobic capacity. 9 Indeed, failure to reduce PVR during exercise in early-stage HFpEF is associated with increased risk of HF hospitalization during long-term follow-up. 33 Thus, there is a pressing need for therapies that improve pulmonary vascular function and, therefore, RV-PA coupling during exercise in HFpEF. 5, 6 In healthy adults, PVR decreases during exercise as pulmonary blood flow increases, because of the combination of vasodilation, pulmonary vascular recruitment, and enhanced distensibility. 34 Normal exercise-mediated reduction in PVR is lost in patients with HFpEF, 9,10,33 but we demonstrate that this impaired vasodilation is partly reversible with albuterol. The potential role of pulmonary vascular-targeted therapy represents an area of intense interest in the field of HFpEF. 20, 21, 25, 26, [35] [36] [37] [38] [39] [40] [41] [42] One potential concern is that reduction in PVR in the setting of LV diastolic dysfunction may increase left atrial hypertension and cause worsening pulmonary congestion. 19 This effect has been observed with direct NO administration, 19 as well as with the phosphodiesterase Error bars indicate SE. P values represent the difference in slopes by t test before and after study drug. January 18, 2019 5 inhibitor sildenafil, 20 which may account for its neutral effects in some trials 36, 37 and negative effect in another.
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Effects on the Left Heart
An important observation from the current study was that albuterol did not increase PCWP. Despite this absent effect on pulmonary capillary hydrostatic pressure, there was an increase in the transmural distending pressure that drives LV filling. Measured intravascular pressures reflect the sum of the transmural distending pressure and external pressure applied to the vessel (or chamber) where measurements are obtained. The external pressure on the LV and atrium, mediated by the pericardium and right-sided chambers, is best approximated by RA pressure. 27 Thus, the LV transmural pressure can be calculated as the difference between intracavitary left heart filling pressure (PCWP) and external pressure (RA). [27] [28] [29] The LV transmural pressure more accurately reflects LV end diastolic volume or true preload. 28 We have recently reported that patients with HFpEF and advanced pulmonary vascular disease (elevated resting PVR) display a reduction in LV transmural pressure during exercise, which compromises cardiac output reserve through failure of the Frank-Starling mechanism, even as PCWP increases. 18 The current data show that albuterol can target this pathophysiology even in patients without marked elevation in resting PVR because transmural pressure was improved in relation to the degree of pulmonary vasodilation with exercise ( Figure 3) . The fact that PVR reduction from albuterol improved exercise cardiac output by 25% speaks to the relevance of pulmonary vascular disease as a viable target in patients with all stages of HFpEF, particularly because limitations in cardiac output reserve are known to be an important contributor to exercise intolerance in this cohort. 9, 43, 44 
β-Agonists in HFpEF
Enhanced sympathetic drive plays a fundamental role in the pathophysiology of HF with reduced ejection fraction, and β-blockers represent a cornerstone in its management. However, similar favorable effects of β-blockers have not been observed in HFpEF. 45 In mice, β-agonists elicit pulmonary vasodilation by enhancing NO signaling. 46 We previously demonstrated in a non-placebo-controlled trial that the nonspecific β-agonist dobutamine substantially improves PA vascular tone in HFpEF, to an extent that exceeded what was seen in subjects without HF. 22 Because dobutamine is a parenterally administered drug, and because of its potent β1-mediated inotropic effects, it is not suitable for chronic administration in HFpEF.
In contrast, albuterol can be administered via metered dose inhaler or nebulizer and is more β2 selective than dobutamine, suggesting that this might be better option for chronic use. In this acute trial, we observed favorable effects of albuterol on PA resistance and compliance during exercise, where vascular and cardiac abnormalities are the most limiting in HFpEF. 9 Vasodilation in the systemic circulation was also observed with albuterol. Although the proportional reductions in systemic arterial pressure during exercise (3%-6%) were far less than corresponding effects in the pulmonary circulation (18%-20%), a systemic vasodilator effect might have also contributed to the salutary effects of albuterol on cardiac output reserve, which is limited, in part, by abnormal systemic vasodilation in HFpEF. 9, 43 The mechanisms by which albuterol acts as a pulmonary vasodilator are unclear but may relate to activation of β-receptors in vascular endothelium to increase NO, direct effects on vascular smooth muscle to reduce vasoconstriction, or indirect effects mediated by alterations in lung function and fluid homeostasis. Indeed, type I and II alveolar pneumocytes express β2 receptors that regulate fluid transit across the alveolar-capillary interface, and acute treatment with albuterol was recently shown to facilitate fluid removal from the alveolar space. 47 Because PVR is directly correlated with lung water content in patients with HFpEF, 48 this effect may contribute, in part, to the beneficial hemodynamic effects observed with albuterol in this trial. Activation of the β2 adrenoreceptor in vascular smooth muscle reduces tone and thus arteriolar resistance, and β2 receptors have also been localized to PA endothelium, where agonist activity promotes vasorelaxation in an endothelial NO synthase-dependent manner. 46 Finally, it is also possible that bronchodilator effects might alter ventilation-perfusion matching and secondarily impact pulmonary vascular tone.
Clinical Implications
Albuterol and other inhaled β-agonists are safe, inexpensive, and widely available. The current data call for the implementation of larger multicenter clinical trials to test the chronic effects of β-agonists in HFpEF-a disorder for which no proven treatment exists. Although recent and ongoing trials have moved toward requiring elevated PVR for inclusion, the current study enrolled a cohort of subjects with earlier stage HFpEF, where PVR was not dramatically elevated at rest but failed to drop appropriately on exercise, and RV function was not profoundly impaired. 9, 10, 33 The current data serve as an important proof of concept that PA vascular-targeted therapies may be beneficial even among HFpEF patients without advanced pulmonary vascular disease. 5, 6 Further study is required in HFpEF patients with more abnormal PVR and RV dysfunction, to determine whether β-agonists may also be effective in this cohort.
In addition, because elevation in PVR is common to virtually all forms of PH, it may be that β-agonists could improve PA vascular function and clinical status in other cohorts, including patients with isolated pulmonary vascular disease (group 1), PH because of chronic lung disease (group 3), or even thromboembolic disease (group 4). The current data revealing favorable effects of albuterol also suggest that there could be deleterious effects on pulmonary and systemic vascular tone with β-adrenergic antagonists, particularly nonselective antagonists.
Limitations
This is a single-center study from a tertiary referral center and as such has inherent limitations relating to both selection and referral bias. However, the use of invasive hemodynamics during exercise was necessary to the study design to obtain the primary and secondary end points, and the invasive data provide robust verification in the diagnosis of HFpEF. The sample size is modest, limiting subgroup analyses, but the trial was well powered to test the hypothesis proposed. Because the focus of this trial was on pulmonary vascular function and RV-PA coupling, evaluations of LV functional responses to albuterol were not performed. The effects of albuterol on pulmonary function tests and gas diffusion were not assessed. This was an acute, proof-of-concept study, and chronic effects of albuterol were not examined. Further studies testing more clinically meaningful end points, such as exercise capacity and symptoms, are needed to determine whether the salutary hemodynamic effects of β-agonists in HFpEF will improve patient-centric outcomes.
Conclusions
Albuterol improves pulmonary vasodilation during exercise in patients with HFpEF, leading to enhanced RV-PA coupling, improved cardiac output reserve, and more favorable left heart distension without untoward elevation in pulmonary venous pressures. Further study is needed to determine the chronic efficacy of β-agonists to improve clinical status in patients with HFpEF, as well as other causes of pulmonary hypertension.
Sources of Funding
B.A. Borlaug is supported by the National Institutes of Health (NIH; R01 HL128526, R01 HL126638, U01 HL125205, and U10 HL110262). Y.N.V. Reddy is supported by T32 HL007111 from the NIH and a Fellow grant from the Heart Failure Society of America. M. Obokata is supported by a research fellowship from the Uehara Memorial Foundation, Japan.
